293 related articles for article (PubMed ID: 27353101)
1. [Clinical study on locally advanced rectal cancer patients with pathological complete response after neoadjuvant chemoradiotherapy].
Chen G; Zhang R; Wu X; Lu Z; Ding P; Pan Z; Wan D
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Jun; 19(6):664-7. PubMed ID: 27353101
[TBL] [Abstract][Full Text] [Related]
2. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
[No Abstract] [Full Text] [Related]
3. [Expression of CD133 in rectal cancer tissues and its relationship with neoadjuvant chemoradiotherapy].
Li D; Wu H; Feng R; Zhong D; Luo Y; Xiao Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Jun; 19(6):690-4. PubMed ID: 27353106
[TBL] [Abstract][Full Text] [Related]
4. [Comparison of short-term efficacy and perioperative safety between neoadjuvant therapy and total neoadjuvant therapy in patients with locally advanced rectal cancer].
Zhai ZW; Zhang KN; Wang C; Han JG; Ma HC; Wei GH; Yang Y; Wang ZJ
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):274-280. PubMed ID: 32192307
[No Abstract] [Full Text] [Related]
5. Tumour regression grading after chemoradiotherapy for locally advanced rectal cancer: a near pathologic complete response does not translate into good clinical outcome.
Swellengrebel HA; Bosch SL; Cats A; Vincent AD; Dewit LG; Verwaal VJ; Nagtegaal ID; Marijnen CA
Radiother Oncol; 2014 Jul; 112(1):44-51. PubMed ID: 25018000
[TBL] [Abstract][Full Text] [Related]
6. [Feasibility study on Xelox (capecitabine plus oxapliplatin) in the volumetric modulated arc therapy (VMAT)-based preoperative chemoradiotherapy for locally advanced rectal cancer].
Xiao L; Huang R; You K; Chang H; Qiu B; Xiao W; Chen L; Gao Y; Liu M
Zhonghua Wei Chang Wai Ke Za Zhi; 2014 Mar; 17(3):219-24. PubMed ID: 24671807
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of neoadjuvant chemoradiotherapy with oxaliplatin and capecitabine for rectal cancer.
Zhao L; Bai C; Shao Y; Guan M; Jia N; Xiao Y; Qiu H; Zhang F; Yang T; Zhong G; Chen S
Cancer Lett; 2011 Nov; 310(2):134-9. PubMed ID: 21782322
[TBL] [Abstract][Full Text] [Related]
8. Preoperative Volumetric Modulated Arc Therapy With Simultaneous Integrated Boost for Locally Advanced Distal Rectal Cancer.
Yang Y; Liu Q; Jia B; Du X; Dai G; Liu H; Chen J; Zeng M; Wen K; Zhu Y; Wang Y; Feng L
Technol Cancer Res Treat; 2019 Jan; 18():1533033818824367. PubMed ID: 30803368
[TBL] [Abstract][Full Text] [Related]
9. [Neoadjuvant chemoradiotherapy with capecitabine and oxaliplatin for the treatment of locally advanced lower rectal cancer].
Murata K; Okamura S; Okubo H; Owada Y; Nishigaki T; Wada Y; Kato R; Makino S; Takeoka T; Okada K; Fukuchi N; Ebisui C; Kinuta M
Gan To Kagaku Ryoho; 2013 Nov; 40(12):2020-2. PubMed ID: 24393999
[TBL] [Abstract][Full Text] [Related]
10. Tumor Volume as Predictor of Pathologic Complete Response Following Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer.
Lutsyk M; Awawda M; Gourevich K; Ben Yosef R
Am J Clin Oncol; 2021 Sep; 44(9):482-486. PubMed ID: 34269693
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant oxaliplatin and capecitabine combined with bevacizumab plus radiotherapy for locally advanced rectal cancer: results of a single-institute phase II study.
Yu X; Wang QX; Xiao WW; Chang H; Zeng ZF; Lu ZH; Wu XJ; Chen G; Pan ZZ; Wan DS; Ding PR; Gao YH
Cancer Commun (Lond); 2018 May; 38(1):24. PubMed ID: 29784042
[TBL] [Abstract][Full Text] [Related]
12. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of capecitabine and oxaliplatin administered prior to and then concomitant to radiotherapy in high risk locally advanced rectal cancer.
Gao YH; An X; Sun WJ; Cai J; Cai MY; Kong LH; Lin JZ; Liu GC; Tang JH; Wu XJ; Chen G; Pan ZZ; Ding PR
J Surg Oncol; 2014 Apr; 109(5):478-82. PubMed ID: 24288203
[TBL] [Abstract][Full Text] [Related]
14. Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53.
Chiorean EG; Sanghani S; Schiel MA; Yu M; Burns M; Tong Y; Hinkle DT; Coleman N; Robb B; LeBlanc J; Clark R; Bufill J; Curie C; Loehrer PJ; Cardenes H
Cancer Chemother Pharmacol; 2012 Jul; 70(1):25-32. PubMed ID: 22610353
[TBL] [Abstract][Full Text] [Related]
15. Prognosis factors for recurrence in patients with locally advanced rectal cancer preoperatively treated with chemoradiotherapy and adjuvant chemotherapy.
Arredondo J; Baixauli J; Beorlegui C; Arbea L; Rodríguez J; Sola JJ; Chopitea A; Hernández-Lizoáin JL
Dis Colon Rectum; 2013 Apr; 56(4):416-21. PubMed ID: 23478608
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II Study.
Eisterer W; Piringer G; DE Vries A; Öfner D; Greil R; Tschmelitsch J; Samonigg H; Sölkner L; Gnant M; Thaler J;
Anticancer Res; 2017 May; 37(5):2683-2691. PubMed ID: 28476845
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of neoadjuvant intensity-modulated radiotherapy with concurrent capecitabine for locally advanced rectal cancer.
Wang L; Li ZY; Li ZW; Li YH; Sun YS; Ji JF; Gu J; Cai Y
Dis Colon Rectum; 2015 Feb; 58(2):186-92. PubMed ID: 25585076
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant capecitabine and oxaliplatin (XELOX) combined with bevacizumab for high-risk localized rectal cancer.
Hasegawa J; Nishimura J; Mizushima T; Miyake Y; Kim HM; Takemoto H; Tamagawa H; Noura S; Fujii M; Fujie Y; Kato T; Miwa H; Takemasa I; Ikeda M; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M
Cancer Chemother Pharmacol; 2014 May; 73(5):1079-87. PubMed ID: 24595805
[TBL] [Abstract][Full Text] [Related]
19. Effect of neoadjuvant cetuximab, capecitabine, and radiotherapy for locally advanced rectal cancer: results of a phase II study.
Sun PL; Li B; Ye QF
Int J Colorectal Dis; 2012 Oct; 27(10):1325-32. PubMed ID: 22430888
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial.
Chua YJ; Barbachano Y; Cunningham D; Oates JR; Brown G; Wotherspoon A; Tait D; Massey A; Tebbutt NC; Chau I
Lancet Oncol; 2010 Mar; 11(3):241-8. PubMed ID: 20106720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
